Generalized Pustular Psoriasis (GPP) Market

The global Generalized Pustular Psoriasis (GPP) Market is valued at USD 18.3 Billion in 2023 and is projected to reach a value of USD 31.73 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 6.3% between 2024 and 2032. The market is driven by the rising incidence of autoimmune diseases, including psoriasis.

Key Highlights

• Generalized pustular psoriasis (GPP) is a rare and severe type of autoimmune skin disease, marked by chronic inflammation and an accelerated rate of skin cell production
• Based on the Treatment, the TNFa antagonists category accounted for significant market share of 66.5% in 2023
• North America dominated the market with 37.5% market share in 2023

Treatment Overview

​The Treatment segment is divided into Topical Agents, Non-biologic agents, Biologic agents, TNFa antagonists, Antibiotics, Others. The TNFa antagonists segment held the dominant share in 2023, accounting for significant market share of 66.5%.

TNF-alpha antagonists are considered the first-line treatment for psoriasis, including all its types. The TNF inhibitors, infliximab and adalimumab, are FDA-approved for various forms of psoriasis. Recently, FDA approvals for biosimilar versions of adalimumab have increased its use in treating generalized pustular psoriasis. For example, in March 2023, Sandoz received FDA approval for a citrate-free, high-concentration formulation of its adalimumab biosimilar, Hyrimoz. In the same month, Celltrion USA gained FDA approval for its biosimilar adalimumab-aaty (Yuflyma), also in a citrate-free, high-concentration formulation. Additionally, Amgen's Amjevita was the first biosimilar launched in January 2023, while Hyrimoz and other adalimumab biosimilars were launched beginning in July 2023.

Regional Overview

In 2023, the North America captured 37.5% of the revenue share.

North America Generalized Pustular Psoriasis (GPP) market is driven by the prevalence of generalized pustular psoriasis. According to a Boehringer Ingelheim publication, recent estimates suggest a combined prevalence of approximately 9 per 100,000 in Sweden and the U.S., and about 3 per 100,000 in Japan. Despite the low numbers, the condition’s prevalence is noticeable in the U.S. and other regions due to its rarity. Additionally, the presence of major pharmaceutical companies like Johnson & Johnson, Bristol Myers Squibb, and Pfizer, which are heavily invested in the research and development of drugs and therapies for generalized pustular psoriasis, further strengthens North America's leading position in the market.

Asia Pacific region is anticipated to grow at fastest rate during the forecast period driven by the increasing awareness of rare diseases, improved healthcare infrastructure, and a rising focus on advanced biologic therapies. Countries like China and Japan are seeing significant advancements in the diagnosis and treatment of GPP, supported by government initiatives and the introduction of innovative therapies, such as the launch of the first biologic agent for GPP in China. Additionally, the growing presence of pharmaceutical companies in the region and the expansion of clinical trials are further fueling market growth.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Increased Investment in R&D: Pharmaceutical companies are ramping up research and development efforts to create innovative therapies for GPP, given the unmet medical need and the rare nature of the condition
• Regulatory Advancements: More regulatory bodies, such as the U.S. FDA, are accelerating approvals for novel GPP treatments, leading to a faster introduction of breakthrough drugs in global markets
• Rising Patient Awareness and Diagnosis: Growing awareness about GPP among patients and healthcare providers is driving earlier diagnosis and treatment, which in turn is boosting demand for new and effective therapies

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Growing number of ongoing clinical trials for generalized pustular psoriasis (GPP)

The market is fueled by the rising prevalence of the condition and advancements in drug development strategies. For example, in October 2023, AnaptysBio, Inc. reported positive top-line results from its global Phase 3 GEMINI trial, which assessed the safety and efficacy of imsidolimab, an interleukin-targeting drug. According to clinicaltrials.gov, Shanghai Huaota Biopharmaceutical Co., Ltd. is also conducting a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult GPP patients. Additionally, Pfizer is running a clinical trial to assess the safety and effectiveness of Infliximab BS for intravenous infusion in treating various forms of psoriasis, including pustular psoriasis, with a study start date in October 2019 and an estimated completion date of May 2025.

Side Effects and Safety Concerns

The risk of side effects associated with medications for Generalized Pustular Psoriasis (GPP) can significantly impact patient behavior and market dynamics. Many treatments, especially biologics and immunomodulators, can cause adverse effects such as infections, allergic reactions, and other systemic issues. When patients are informed about these potential side effects, they may hesitate to initiate treatment or may not follow through with prescribed therapies, fearing complications. This reluctance can lead to suboptimal disease management, resulting in worsened symptoms and a lower quality of life.

Competitive Landscape

The Generalized Pustular Psoriasis (GPP) market is evolving rapidly, with several key players focusing on innovative treatment solutions for this rare and severe skin condition. Boehringer Ingelheim has taken a significant lead with the launch of SPEVIGO, the first U.S. FDA-approved treatment for GPP flares in adults, and the subsequent introduction of the world's first biologic agent for GPP in China. Other pharmaceutical companies are actively conducting research and development to introduce novel therapies, particularly in the biologic and immunotherapy segments, aiming to address unmet medical needs. As the market expands, the competition is expected to intensify with more companies seeking regulatory approvals for breakthrough treatments to capture a share of this niche but growing market.

The key players in the global Generalized Pustular Psoriasis (GPP) market include - Eli Lilly and Company, Amgen Inc., Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, UCB Inc., Pfizer Inc., AbbVie Inc., Novartis AG, Astellas Pharma Inc. among others.

Recent Market Developments

Boehringer Ingelheim Introduces World’s First Biologic Agent for Generalized Pustular Psoriasis (GPP) in China

• In September 2022, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved SPEVIGO, marking the first treatment available for adults’ experiencing flares of generalized pustular psoriasis (GPP)

U.S. FDA Approves SPEVIGO: First Treatment for Generalized Pustular Psoriasis (GPP) Flares in Adults

• In May 2023, Boehringer Ingelheim held ceremonies in China to launch the world’s first biologic agent specifically designed to treat GPP

The global Generalized Pustular Psoriasis (GPP) market can be categorized as Treatment, Route of Administration, End User and Region.